Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Net Income (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Net Income for 9 consecutive years, with $85.4 million as the latest value for Q4 2025.

  • Quarterly Net Income fell 35.12% to $85.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$334000.0 through Dec 2025, down 100.12% year-over-year, with the annual reading at -$362000.0 for FY2025, 100.13% down from the prior year.
  • Net Income hit $85.4 million in Q4 2025 for Protagonist Therapeutics, up from -$39.3 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $207.4 million in Q1 2024 to a low of -$41.0 million in Q2 2022.
  • Historically, Net Income has averaged $3.4 million across 5 years, with a median of -$31.0 million in 2021.
  • Biggest five-year swings in Net Income: crashed 335.45% in 2021 and later soared 714.87% in 2024.
  • Year by year, Net Income stood at $88.9 million in 2021, then crashed by 138.55% to -$34.3 million in 2022, then surged by 179.78% to $27.3 million in 2023, then soared by 381.7% to $131.7 million in 2024, then plummeted by 35.12% to $85.4 million in 2025.
  • Business Quant data shows Net Income for PTGX at $85.4 million in Q4 2025, -$39.3 million in Q3 2025, and -$34.8 million in Q2 2025.